Table 25.
Recommended Monitoring for Patients Taking Other Antiarrhythmic Drugs
| Drug | Baseline Testing | Follow-Up Testing | Additional Follow-Up Testing |
|---|---|---|---|
| Dofetilide | 12-lead ECG* Continuous electrocardiographic monitoring during 3-d hospitalization for dofetilide initiation Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl |
In 3–6 mo: 1 2-lead ECG* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl |
Every 3–6 mo (more frequently for patients concomitantly taking other QT interval-prolonging drugs or with changing kidney function: 1 2-lead ECG* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl |
| Dronedarone | 12-lead ECG* AST† ALT† |
Within first 6 mo: AST† ALT† |
– |
| Ibutilide | 12-lead ECG* Determination of serum potassium and magnesium concentrations and correction of hypokalemia and/or hypomagnesemia is recommended before initiation of the infusion |
Continuous electrocardiographic monitoring for assessment of QTc interval duration is recommended for at least 4 h after infusion or until the QTc has returned to baseline to minimize the risk of ibutilide-associated TdP | – |
| Procainamide | 12-lead ECG* BP |
Electrocardiographic monitoring for assessment of rhythm, QRS width and QTc interval is recommended during the infusion to minimize the risk of procainamide-associated ventricular proarrhythmia, including TdP BP monitoring is recommended during the infusion to detect clinically relevant hypotension | – |
| Sotalol | 12-lead ECG* Continuous electrocardiographic monitoring during 3-d hospitalization for sotalol initiation Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl |
In 3–6 mo: 12-lead ECG* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl |
Every 3–6 mo (more frequently for patients concomitantly taking other QT interval-prolonging drugs or with changing kidney function: 12-lead ECG* Serum potassium and magnesium concentration Serum creatinine for estimation of CrCl |
*
Assess rhythm and calculate QTc.
†
To facilitate early detection of potential dronedarone-associated hepatotoxicity.
ALT indicates alanine transaminase; AST, aspartame transaminase; BP, blood pressure; ECG, electrocardiogram; CrCl, creatinine clearance; and TdP, torsades de pointes.